Daniel Austin, DO
Family Medicine · Pittsburgh, PANPI 1407274699
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,327 of the $3,854 with a category attached, or 86.3%. It is spread thinly across 24 manufacturers, the largest accounting for just 13.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,064 and has fallen 74.3% since, to $531 in 2024.
Across 227 payments — averaging $16.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$506
- Novo Nordisk$480
- GSK$395
- AbbVie$354
- AstraZeneca$312
- Johnson & Johnson$244
- plus $2K from 18 others
Across 74 payments — averaging $8023.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$404K
- Sanofi Pasteur Inc.$60K
- Pfizer$58K
- Boehringer Ingelheim$42K
- Boehringer Ingelheim Pharma GmbH & Co.kg$15K
- Kowa Research Institute, Inc.$13K
- plus $1K from 2 others
What the payments were for
- Speaking & faculty fees$160%
- Travel & lodging$50613%
- Food & beverage$3,32786%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 8 | $506 |
| Novo Nordisk | 29 | $480 |
| GSK | 29 | $395 |
| AbbVie | 19 | $354 |
| AstraZeneca | 18 | $312 |
| Johnson & Johnson | 18 | $244 |
| Amgen | 12 | $204 |
| Lilly USA, LLC | 13 | $181 |
| Pfizer | 13 | $175 |
| Sanofi-aventis U.S. LLC | 12 | $143 |
| Merck | 11 | $131 |
| Astellas Pharma US Inc | 6 | $105 |
| Biohaven Pharmaceuticals, Inc. | 7 | $103 |
| Amarin Pharma, Inc. | 5 | $99 |
| Boehringer Ingelheim | 7 | $94 |
| Esperion Therapeutics, Inc. | 3 | $60 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $44 |
| Urovant Sciences Inc | 2 | $42 |
| Nestle Healthcare Nutrition Inc. | 2 | $39 |
| Novartis | 2 | $28 |
| Arbor Pharmaceuticals, Inc. | 2 | $27 |
| E.r. Squibb & Sons, L.L.C. | 2 | $24 |
| Acorda Therapeutics, Inc | 1 | $16 |
How this compares
$3,854 in reported general payments places this provider in the 85th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 382 | $353,095 |
| OzempicSemaglutide | 182 | $232,738 |
| JardianceEmpagliflozin | 72 | $71,648 |
| XareltoRivaroxaban | 53 | $64,211 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 33 | $53,364 |
| MounjaroTirzepatide | 44 | $46,798 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $33,999 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 18 | $33,853 |
| FarxigaDapagliflozin Propanediol | 34 | $31,829 |
| RybelsusSemaglutide | 23 | $29,378 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 36 | $24,440 |
| InvokanaCanagliflozin | 22 | $23,630 |
| MyrbetriqMirabegron | 65 | $22,911 |
| TrulicityDulaglutide | 17 | $22,116 |
| LinzessLinaclotide | 30 | $18,928 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid, Premarin | $175 | $365,818413 claims |
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus | $480 | $315,480238 claims |
| Johnson & JohnsonXarelto, Invokana | $244 | $87,84175 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Shingrix | $395 | $74,772139 claims |
| Boehringer IngelheimJardiance | $94 | $71,64872 claims |
| Lilly USA, LLCMounjaro, Trulicity | $181 | $68,91461 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $143 | $33,85318 claims |
| AstraZenecaFarxiga | $312 | $31,82934 claims |
| Astellas Pharma US IncMyrbetriq | $105 | $22,91165 claims |
| AbbVieLinzess, Synthroid | $354 | $22,37486 claims |
| MerckJanuvia | $131 | $17,75919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Pittsburgh
- Nathan BennettPittsburgh$465K
- Deborah GilboaPittsburgh$60K
- Gregory JaffePittsburgh$38K
- Neil SkolnikJenkintown$904K
- Lisa EspinozaNew Hope$722K
- Christopher Varacallodu Bois$627K
- Paul DoghramjiCollegeville$617K
- Brian DeyarminBethel Park$491K
- Gary OwensGlen Mills$404K
- Mary ZakutneyIrwin$393K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.